Oncotelic Therapeutics Highlights Advanced Oncology Pipeline and CEO's 500+ Patent Portfolio

Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company, has highlighted its comprehensive oncology pipeline and the substantial intellectual property contributions of Chairman and CEO Dr. Vuong Trieu, who holds more than 500 filed patents and 75 issued patents. Dr. Trieu co-developed blockbuster therapeutics Abraxane and Cynviloq, establishing a foundation of innovation that underpins the company's current development strategy.

The company's portfolio includes multiple late-stage candidates addressing significant medical needs. OT-101 is currently in Phase 3 development for pancreatic cancer, while OXi4503 is advancing toward Phase 3 trials for acute myeloid leukemia and myelodysplastic syndromes. CA4P/Fosbretabulin is in late-stage repositioning, demonstrating the company's approach to maximizing the potential of existing compounds. Beyond oncology, Oncotelic is developing AL-101 in Phase 2 trials for Parkinson's disease and sexual dysfunctions, and AL-102 in discovery phase for Alzheimer's disease.

Oncotelic's strategy includes developing multiple pediatric rare disease programs with potential to generate Priority Review Vouchers, which represent valuable regulatory assets that can accelerate drug approval processes. This approach reinforces the company's focus on building value through differentiated biotechnology assets with strong competitive barriers. The company's mission centers on addressing high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by Dr. Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. The company also maintains strategic partnerships through joint ventures, currently owning 45% of GMP Bio, a joint venture under Dr. Trieu's leadership that is advancing its own pipeline of drug candidates. This structure further strengthens Oncotelic's strategic position in oncology and rare disease therapeutics. For additional information, visit https://www.oncotelic.com/.

The significance of Oncotelic's pipeline development lies in its potential to address some of the most challenging medical conditions with limited treatment options. The advancement of multiple candidates into late-stage clinical trials, combined with the substantial intellectual property portfolio, positions the company to potentially bring transformative treatments to market. This development matters to patients facing pancreatic cancer, AML/MDS, and rare pediatric diseases, as well as to the biotechnology industry, where innovative approaches to drug development and intellectual property management can drive both medical progress and commercial success.